{"id":"https://openalex.org/W2431442613","doi":null,"title":"Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.","display_name":"Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.","publication_year":1989,"publication_date":"1989-09-01","ids":{"openalex":"https://openalex.org/W2431442613","mag":"2431442613","pmid":"https://pubmed.ncbi.nlm.nih.gov/2681444"},"language":"en","primary_location":{"id":"pmid:2681444","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2681444","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of interferon research","raw_type":"Clinical Trial"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061549536","display_name":"Loretta Marie Itri","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L M Itri","raw_affiliation_strings":["Department of Clinical Research and Development, Hoffmann-La Roche, Inc., Nutley, NJ 07110"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Research and Development, Hoffmann-La Roche, Inc., Nutley, NJ 07110","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052025506","display_name":"Morris Sherman","orcid":"https://orcid.org/0000-0003-4983-3049","observed_orcids":["https://orcid.org/0000-0003-4983-3049"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M I Sherman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109043546","display_name":"Alicia V. Palleroni","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A V Palleroni","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007012742","display_name":"Lydia M. Evans","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L M Evans","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050240205","display_name":"Ly-Le Tran","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L L Tran","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110877602","display_name":"M. Campion","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Campion","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5074634012","display_name":"R Chizzonite","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R Chizzonite","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.599,"has_fulltext":false,"cited_by_count":37,"citation_normalized_percentile":{"value":0.63694045,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"9 Suppl 1","issue":null,"first_page":"S9","last_page":"15"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.8676999807357788,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.8676999807357788,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.06800000369548798,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11668","display_name":"interferon and immune responses","score":0.02590000070631504,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neutralizing-antibodies","display_name":"neutralizing antibodies","score":0.8339999914169312},{"id":"https://openalex.org/keywords/interferon-alfa-2a","display_name":"interferon alfa-2a","score":0.9539999961853027},{"id":"https://openalex.org/keywords/anti-interferon-antibodies","display_name":"anti-interferon antibodies","score":0.8360000252723694},{"id":"https://openalex.org/keywords/antibody-incidence","display_name":"antibody incidence","score":0.7789999842643738},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.9190000295639038},{"id":"https://openalex.org/keywords/route-of-administration","display_name":"route of administration","score":0.8330000042915344},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.7649999856948853},{"id":"https://openalex.org/keywords/cumulative-dose","display_name":"cumulative dose","score":0.9800000190734863},{"id":"https://openalex.org/keywords/interferon-therapy","display_name":"interferon therapy","score":0.5619999766349792},{"id":"https://openalex.org/keywords/therapeutic-proteins","display_name":"therapeutic proteins","score":0.4519999921321869},{"id":"https://openalex.org/keywords/antibody-detection-assay","display_name":"antibody detection assay","score":0.3619999885559082}],"concepts":[{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.8258845210075378},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.6105260252952576},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5944162607192993},{"id":"https://openalex.org/C63363279","wikidata":"https://www.wikidata.org/wiki/Q5133848","display_name":"Clinical significance","level":2,"score":0.5526512265205383},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.5271115899085999},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.49190330505371094},{"id":"https://openalex.org/C2779261636","wikidata":"https://www.wikidata.org/wiki/Q7003054","display_name":"Neutralizing antibody","level":3,"score":0.4908497929573059},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.4715304970741272},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.46757772564888},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4047199785709381},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2906065583229065},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000906","descriptor_name":"Antibodies","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D000906","descriptor_name":"Antibodies","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000937","descriptor_name":"Antigen-Antibody Reactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007370","descriptor_name":"Interferon Type I","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:2681444","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2681444","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of interferon research","raw_type":"Clinical Trial"},{"id":"mag:2431442613","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2681444","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2435777407","https://openalex.org/W2128054156","https://openalex.org/W2010451278","https://openalex.org/W1975978239","https://openalex.org/W2414163076","https://openalex.org/W2002871050","https://openalex.org/W2412948981","https://openalex.org/W2414855299","https://openalex.org/W2403518770","https://openalex.org/W2066569831"],"abstract_inverted_index":{"In":[0],"clinical":[1,44,76,107,181],"trials":[2],"with":[3,70,90,160],"a":[4,14,28,84,191],"range":[5],"of":[6,8,18,47,53,63,86,96,133,140,172,194,198],"doses":[7],"recombinant":[9],"interferon-alpha":[10],"2a,":[11],"we":[12],"observed":[13],"25%":[15],"overall":[16],"incidence":[17,74],"neutralizing":[19],"antibody":[20,31,41,111,124,156],"development.":[21],"Careful":[22],"data":[23],"analysis":[24,193],"did":[25],"not":[26,115],"reveal":[27],"relationship":[29,122],"between":[30,123],"development":[32,42,112,125,157],"and":[33,43,51,75,126,142,164,183],"therapeutic":[34,58,200],"response.":[35],"Of":[36],"752":[37],"patients":[38,50,56],"evaluable":[39],"for":[40,83,93,179,190],"response,":[45],"31%":[46],"the":[48,54,61,94,143,152,161,170,195],"antibody-positive":[49],"28%":[52],"antibody-negative":[55],"had":[57],"responses.":[59],"Although":[60],"formation":[62],"anti-IFN":[64],"antibodies":[65,98],"seems":[66],"to":[67,81,155],"be":[68],"associated":[69],"most":[71],"IFN":[72,97],"preparations,":[73],"significance":[77],"have":[78,99,113],"been":[79,100,116],"difficult":[80],"determine":[82],"number":[85],"reasons.":[87],"Different":[88],"assays":[89],"differing":[91],"sensitivities":[92],"detection":[95],"utilized":[101],"in":[102],"different":[103],"studies.":[104],"Additionally,":[105],"important":[106],"variables":[108,182],"that":[109,151],"affect":[110],"often":[114],"carefully":[117],"controlled":[118],"or":[119],"analyzed.":[120],"The":[121],"multiple":[127],"related":[128],"factors,":[129],"such":[130],"as":[131,167,169],"route":[132,171],"administration,":[134],"dose":[135,162],"regimen,":[136],"cumulative":[137,165],"dose,":[138,166],"duration":[139],"treatment,":[141],"underlying":[144],"disease,":[145],"requires":[146],"clarification.":[147],"Initial":[148],"analyses":[149],"suggest":[150],"median":[153],"time":[154],"may":[158],"vary":[159],"regime":[163],"well":[168],"administration.":[173],"Carefully":[174],"designed":[175],"prospective":[176],"studies":[177],"controlling":[178],"influential":[180],"utilizing":[184],"standardized":[185],"assay":[186],"techniques":[187],"are":[188],"required":[189],"meaningful":[192],"antigenic":[196],"potential":[197],"all":[199],"protein":[201],"products.":[202]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2017,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}